Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 3
1994 2
1995 1
1997 2
1998 2
1999 2
2000 1
2001 1
2002 2
2003 1
2004 2
2014 1
2017 1
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Proteomics in neuropsychiatric disorders.
Rohlff C. Rohlff C. Int J Neuropsychopharmacol. 2001 Mar;4(1):93-102. doi: 10.1017/S1461145701002267. Int J Neuropsychopharmacol. 2001. PMID: 11343634 Free article. Review.
Proteomic approaches in drug discovery and development.
Soares HD, Williams SA, Snyder PJ, Gao F, Stiger T, Rohlff C, Herath A, Sunderland T, Putnam K, White WF. Soares HD, et al. Among authors: rohlff c. Int Rev Neurobiol. 2004;61:97-126. doi: 10.1016/S0074-7742(04)61005-1. Int Rev Neurobiol. 2004. PMID: 15482813 Review. No abstract available.
MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.
Merlino G, Fiascarelli A, Bigioni M, Bressan A, Carrisi C, Bellarosa D, Salerno M, Bugianesi R, Manno R, Bernadó Morales C, Arribas J, Dusek RL, Ackroyd JE, Pham PH, Awdew R, Aud D, Trang M, Lynch CM, Terrett J, Wilson KE, Rohlff C, Manzini S, Pellacani A, Binaschi M. Merlino G, et al. Among authors: rohlff c. Mol Cancer Ther. 2019 Sep;18(9):1533-1543. doi: 10.1158/1535-7163.MCT-18-0624. Epub 2019 Jun 21. Mol Cancer Ther. 2019. PMID: 31227646
Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
Krupka C, Lichtenegger FS, Köhnke T, Bögeholz J, Bücklein V, Roiss M, Altmann T, Do TU, Dusek R, Wilson K, Bisht A, Terrett J, Aud D, Pombo-Villar E, Rohlff C, Hiddemann W, Subklewe M. Krupka C, et al. Among authors: rohlff c. Oncotarget. 2017 May 30;8(22):35707-35717. doi: 10.18632/oncotarget.16060. Oncotarget. 2017. PMID: 28415689 Free PMC article.
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models.
Gaudio E, Tarantelli C, Spriano F, Guidetti F, Sartori G, Bordone R, Arribas AJ, Cascione L, Bigioni M, Merlino G, Fiascarelli A, Bressan A, Adjeiwaa Mensah A, Golino G, Lucchini R, Bernasconi E, Rossi D, Zucca E, Stussi G, Stathis A, Boyd RS, Dusek RL, Bisht A, Attanasio N, Rohlff C, Pellacani A, Binaschi M, Bertoni F. Gaudio E, et al. Among authors: rohlff c. Haematologica. 2020 Nov 1;105(11):2584-2591. doi: 10.3324/haematol.2019.227215. Haematologica. 2020. PMID: 33131247 Free PMC article.
23 results